Expert Outlook: Exact Sciences Through The Eyes Of 5 Analysts
Portfolio Pulse from Benzinga Insights
Analysts have varied opinions on Exact Sciences (NASDAQ:EXAS) with a mix of bullish and somewhat bullish ratings over the past quarter. The average 12-month price target has decreased by 6.48% to $83.0. Key analysts have lowered their price targets, reflecting a negative shift in sentiment.
June 26, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Analysts have shown a negative shift in sentiment towards Exact Sciences, lowering the average 12-month price target by 6.48% to $83.0. Key analysts from BTIG, Canaccord Genuity, and Citigroup have reduced their price targets, reflecting concerns about the company's future performance.
The decrease in the average price target and the lowering of targets by key analysts indicate a negative shift in sentiment towards Exact Sciences. This could lead to a short-term decline in the stock price as investors react to the revised expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100